YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==CONJUNCTIVITIS== 18 AUTHOR Hubbard C TITLE Conjunctivitis SOURCE On Contin. Pract.; VOL 16 ISS Jul 1989, P4-6, (REF 11) ABSTRACT IPA COPYRIGHT: ASHP The etiology and treatment of bacterial, viral, fungal, parasitic, and allergic conjunctivitis are discussed. 2 AUTHOR CIPRANDI G AUTHOR BUSCAGLIA S AUTHOR CERQUETI MP AUTHOR SACCA S AUTHOR TOSCA M AUTHOR CANONICA GW TITLE Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivitis: A comparative double-blind study. SOURCE J INVEST ALLERGOL CLIN IMMUNOL; 2 (5). 1992. 248-252. ABSTRACT BIOSIS COPYRIGHT: BIOL ABS. Anti-inflammatory drugs, i.e. glucocorticosteroids and NSAIDs (nonsteroidal anti-inflammatory drugs), are often included in the treatment of allergic conjunctivitis. The present study compares the clinical efficacy and safety of topical hydrocortisone, acetylsalicyclic acid (ASA) and piroxicam compared to placebo. The trial, designed as a double-blind, randomized and parallel-group treatment, was carried out in a group of 40 patients suffering from seasonal allergic conjunctivitis due to Parientaria pollen, during the pollen season (June-July, 1990). Patients recived hydrocortisone 0.1% solution, ASA 1% solution, piroxicam 0.5% solution or placebo as eye drops, all one drop in each eye q.i.d. for 14 days. The symptoms were evaluated at baseline and st the end of treatment by the clinician and by patients on a diary card. The hydrocortisone group showed a rapid and significant improvement during the first week of treatment, while ASA and piroxicam reduced symptomatology during the second week of treatment; this difference was statistically significant. At the end of the trial, the active drugs were comparable with regard to clinical efficacy. A statistically significant difference was observed between the active drugs and placebo, while no statistically significant difference was observed among the three drugs. No serious side-effects were observed. The results demonstrate the clinical efficacy of anti-inflammatory drugs in the treatment of pollen-induced allergic conjunctivitis; they also suggest the use of NSAIDs in long-term treatment, as their efficacy has been shown to be closely comparable to that of steroids, while avoiding the well-known side-effects of the latter in prolonged treatment. 3 AUTHOR CIPRANDI G AUTHOR BUSCAGLIA S AUTHOR TOSCA M AUTHOR CANONICA GW TITLE Topical acetylsalicylic acid in the treatment of allergic pollinosic conjunctivitis. SOURCE J INVEST ALLERGOL CLIN IMMUNOL; 2 (1). 1992. 15-18. ABSTRACT BIOSIS COPYRIGHT: BIOL ABS. The pharmacological treatment of allergic conjunctivitis includes the use of topical antiinflammatory drugs, i.e. steroids and NSAIDs (nonsteroidal antiinflammatory drugs), such as acetylsalicylic acid (ASA). However, steroids are not suitable in prolonged treatment, as well as in pollinosis in the Mediterranean area, because of their side effects. The present double-blind study evaluates the topical use of acetylsalicylic acid eye drops (1% solution) compared to placebo in the treatment of patients with seasonal allergic conjunctivitis during the period June-July 1990. The patients were randomized and treated with ASA eye drops or placebo eye drops, both applied as one drop in each eye q.i.d. for 14 days. The severity of symptoms was evaluated before and after treatment by the investigator and the patients. An overall judgement of therapeutic response was expressed independently by the patient and the investigator at the end of the treatment. The ASA-treated group improved significantly compared to the placebo-treated group. No serious side effects were observed. The results confirm the clinical efficacy and safety of topical ASA in the treatment of pollen-induced allergic conjunctivitis. 4 AUTHOR CIPRANDI G AUTHOR CERQUETI PM AUTHOR SACCA S AUTHOR CILLI P AUTHOR CANONICA GW TITLE Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. SOURCE ANN ALLERGY; 65 (2). 1990. 156-158. ABSTRACT BIOSIS COPYRIGHT: BIOL ABS. Thirty patients with allergic conjunctivitis, caused by Parietaria or grass pollens, participated in a double-blind parallel study comparing levocabastine to cromolyn sodium, both given as eye drops. Symptom and sign scores were recorded during a 4-week period. The patients received only these drugs during the time of observation. The evaluation of the clinical signs and symptoms by the clinicians and by the patients revealed a significant improvement of conjunctivitis in all patients. The intergroup comparison was equal in the two groups treated respectively with levocabastine and cromolyn. Therefore, levocabastine and cromolyn are effective in the treatment of pollen-induced allergic conjunctivitis. 10 AUTHOR anon TITLE Ophthalmic levocabastine for allergic conjunctivitis SOURCE Med. Lett. Drugs Ther.; VOL 36 ISS Apr 15 1994, P35-36, (REF ) ABSTRACT IPA COPYRIGHT: ASHP A brief overview of 0.05% ophthalmic solution of levocabastine hydrochoride (Livostin), recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of seasonal allergic conjunctivitis, is presented, including pharmacokinetics, results of clinical studies, adverse effects, dosage, and costs. 24 AUTHOR FRIDAY GA AUTHOR BIGLAN AW AUTHOR HILES DA AUTHOR MURPHEY SM AUTHOR MILLER L AUTHOR ROTHBACH C AUTHOR RAND S TITLE Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4 percent ophthalmic solution. SOURCE AM J OPHTHALMOL; 95 (2). 1983. 169-174. ABSTRACT HEEP COPYRIGHT: BIOL ABS. Patients (31) with ragweed conjunctivitis in an 8-wk, double-masked parallel-group study with cromolyn sodium 4% ophthalmic solution. Analysis of data showed preseason serum IgE antibody to ragweed level was a significant predictor of drug response. Of 16 patients with ragweed IgE values of less than 100 ng/ml, the 9 treated with cromolyn had significantly fewer symptoms during the course of treatment than the 7 in the placebo group. Of the 15 remaining patients, who had IgE levels of more than 100 ng/ml, the 8 treated with cromolyn improved but the difference betwen their symptom scores and those of the 7 patients treated with placebo was not statistically significant. 25 AUTHOR Gibson JR TITLE Trimethoprim-polymyxin B ophthalmic solution in the treatment of presumptive bacterial conjunctivitis: multicenter trial of its efficacy versus neomycin-polymyxin B-gramicidin and chloramphenicol ophthalmic solutions SOURCE J. Antimicrob. Chemother.; VOL 11 ISS Mar 1983, P217-221, (REF 8) ABSTRACT IPA COPYRIGHT: ASHP The efficacy of trimethoprim-polymyxin B (TP) versus chloramphenicol and TP versus neomycin-polymyxin B-gramicidin (NPG) ophthalmic solutions was studied in 230 patients with eye infections given one drop of the solution into each affected eye 4 times daily for 7 days. Of the 5 patients in the TP group withdrawn from the trial, 4 were due to stinging and one due to failure to improve. Of the 4 patients withdrawn in the chloramphenicol group, 3 were due to possible drug related allergic reactions and one due to failure to improve. Of the 2 patients in the NPG group withdrawn from the trial, one was due to the development of bilateral periorbital edema and the other failure to improve. Results showed the TP ophthalmic solution to be effective as NPG and better than chloramphenicol in reducing signs and symptoms of bacterial conjunctivitis. 26 AUTHOR van Rensburg SFJ AUTHOR Gibson JR AUTHOR Harvey SG AUTHOR Burke CA TITLE Trimethoprim-polymyxin ophthalmic solution versus chloramphenicol ophthalmic solution in the treatment of bacterial conjunctivitis SOURCE Pharmatherapeutica; VOL 3 ISS 4 1982, P274-277, (REF 3) ABSTRACT IPA COPYRIGHT: ASHP Forty patients with a diagnosis of presumptive bacterial conjunctivitis were treated with either trimethoprim-polymyxin or chloramphenicol ophthalmic solutions in a randomized, double blind trial. No significant differences could be demonstrated between the results of 7 day therapy with either preparation and signs and symptoms of surface ocular bacterial infection were improved in all patients. No adverse reactions were reported. 27 AUTHOR Patamasucon P AUTHOR Retlig PJ AUTHOR Faust KL AUTHOR Kusmiesz HT AUTHOR Nelson JS TITLE Oral versus topical erythromycin therapies for chlamydial conjunctivitis SOURCE Am. J. Dis. Child.; VOL 136 ISS Sep 1982, P817-821, (REF 33) ABSTRACT IPA COPYRIGHT: ASHP In 41 infants under 4 months of age with chlamydial conjunctivitis, therapy with either 1% erythromycin ophthalmic ointment applied 4 times a day for 21 days or oral erythromycin in divided doses for 21 days was compared. Although both modes of therapy were comparable for treatment of conjunctivitis, oral erythromycin had the advantage of eradicating nasopharyngeal colonization. 28 AUTHOR NIZAMI RM TITLE Treatment of ragweed allergic conjunctivitis with 2 percent cromolyn solution in unit doses. SOURCE ANN ALLERGY; 47 (1). 1981. 5-7. ABSTRACT HEEP COPYRIGHT: BIOL ABS. Previous studies have shown the effectiveness of topical cromolyn solution in the treatment of allergic conjunctivitis. The preservative, phenylethanol, produces an immediate burning or stinging sensation when the drops are first instilled in the eye. A double-blind, crossover, placebo controlled study using 2% cromolyn solution was conducted in 26 patients, without the preservative and supplied in unit doses. They had ragweed pollen-induced conjunctivitis. The active drug was effective in controlling the signs and symptoms of allergic conjunctivitis in 22 of the 26 patients, i.e., 84.6%. Two patients preferred the placebo. There were no complaints of stinging or burning sensation after the instillation of the drops in the eyes. There were no cases of infection of the eye. Without the preservative the cromolyn solution does not damage the soft contact lens.